Ann: Positive IHL-675A in vivo results and FDA Pathway, page-58

PS the fact that IHL has in its announcement referred to Camargo should indicate to all investors the exceptional level to which this BOD operates . They have had success on the trial and already announced how they intend to achieve FDA approval and the required leading consultant Camargo that can get them there . Very strategic and visionary a step ahead at all junctures . They are thorough and think ahead . I am rapt I am in loaded and patient . I have been in it from the outset and topped up and will hold as we are in my view at the beginning of a significant journey that will not only reward shareholders but assist many people suffering from inflammatory ailments .